Actinium Pharmaceuticals, Inc. (ATNM) Form 8-K — Oct 15, 2026
$ATNMForm 8-KItems 5.02, 7.01, 9.01Filed Oct 15, 2026, 5:05 PM ET0001213900-26-109884Original filing
Actinium Pharmaceuticals appointed Matt David, M.D., as Chief Financial Officer and principal financial officer, effective October 14, 2026. Dr. David joins from CorMedix, where he served as CFO from 2020 and later Chief Business Officer, helping guide the company through FDA approval of DefenCath, commercial launch, and a 2025 acquisition. He previously held roles at Ovid Therapeutics and in healthcare investment banking at BofA Merrill Lynch, Piper Jaffray and Thomas Weisel Partners.
Key figures
- Rsus
- 325000
- Salary
- 450000
- Sign On Bonus
- 150000
- Stock Options
- 250000
- Target Bonus Percent
- 40
- Option vesting years
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.